Semax
Also known as: MEHFPGP, Semax Acetate
A synthetic ACTH analog developed in Russia for neuroprotection and cognitive enhancement.
Overview
Semax is a synthetic heptapeptide based on ACTH(4-10) with additional amino acids for stability. Developed in Russia, it has been approved for stroke, cognitive disorders, and optic nerve disease.
Mechanism of Action
Increases BDNF and NGF expression. Modulates dopaminergic and serotonergic systems. Enhances neuroplasticity and protects against oxidative stress. No hormonal (corticosteroid) effects.
Pharmacokinetics
Intranasal administration bypasses BBB. Half-life ~3 minutes but effects last hours. Rapid CNS distribution.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Cognitive Enhancement
300-600 mcg
1-2x daily
2-4 weeks
Intranasal administration
Neuroprotection
900-1200 mcg
2-3x daily
10-14 days
Acute treatment protocol
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Approved in Russia for stroke treatment
- 2Increased BDNF expression in animal studies
- 3Improved cognitive function and memory
- 4Neuroprotective in various disease models
Side Effects & Contraindications
Reported Side Effects
- Mild stimulation
- Nasal irritation
- Headache (rare)
Contraindications
- Acute psychosis
- Pregnancy
Safety Considerations
Well-tolerated. No steroidogenic activity. May cause mild stimulation.
Storage Requirements
Store at 2-8C. Protect from light.
Scientific References
- 1